Ben brings both biopharma expertise and diverse experience. For the past five and a half years, he was a senior manager in PwC’s Health Research Institute. He developed reports on various policy issues and business trends, particularly in the pharma and medtech sectors, provided research for clients and spoke at industry events. Previously, he was a journalist with Pharmaceutical Executive; Medical Marketing & Media, PRWeek and Direct Marketing News; and Ad-Fax Media. During his college days, he taught English in China.
He lives in Orlando, Fla. Outside of work, Ben enjoys playing guitar, welcomes your recommendations for great novels and avidly pursues hiking, biking and other outdoor activities.
Latest From Ben Comer
Clinical-stage biopharma Starton Therapeutics is developing continuous delivery systems and transdermal technologies to improve the safety and efficacy of existing cancer medications, and eschewing VC firms in favor of retail investors. Chair and CEO Pedro Lichtinger recently appeared on Unicorn Hunters, an online reality TV show, to pitch the company to celebrity judges, and the public at large.
A panel of executives, academics and experts discussed the potential for psychedelic therapies, such as MDMA and psilocybin, to revolutionize behavioral health in a recent Demy Colton virtual salon. But with nearly 50 publicly traded companies now developing psychedelics, some panelists expressed concern about a rush to market, and “competition and domination” harshening the buzz.
As the COVID-19 crisis recedes, industry leaders are placing a renewed emphasis on environmental sustainability, from API manufacturing and raw material sourcing to package inserts. As NHS England chair Lord Prior said at BIO Digital, “Climate change is going to make COVID look like a picnic in the park.”
Investment and research into the science of aging – and therapeutics that could slow down or even reverse the aging process – are ramping up. Past clinical failures have given way to new and focused approaches that aim to lengthen “healthspan,” turning the last years of life into the best years of life.
Venture capitalists and industry executives discussed strategies for placing smart bets on emerging gene therapy companies during a recent virtual panel.
In conjunction with In Vivo’s Rising Leaders series, a panel of senior executives representing a wide spectrum of the life sciences industry – from large biopharmaceuticals to small biotech and cancer diagnostics – was convened to discuss what it takes to successfully lead during times of uncertainty and upheaval. Insights on communication strategies, navigating team integrations, supporting diversity and inclusion, and getting the most from multi-generational employees rested on a common theme: valuing people and anticipating workforce needs.